Over the past 2 decades, the incidence of systemic mycoses has increased dramatically. This is primarily due to the increase in the number of at-risk individuals, principally those with impaired immunity, such as transplant recipients, cancer patients receiving chemotherapy, and human immunodeficiency virus-infected patients (2, 17, 24, 32, 37) . The most common fungal pathogens are species of Candida, Cryptococcus, Coccidioides, Aspergillus, and Histoplasma; less common pathogens include agents of zygomycosis (primarily species of Rhizopus, Mucor, Cunninghamella, Apophysomyces, Absidia, and Rhizomucor), hyalohyphomycosis, and phaeohyphomycosis (32) .
Mortality rates associated with systemic mycoses, particularly those involving members of the zygomycetes, remain unacceptably high. Effective treatment requires both an early diagnosis, to facilitate prompt initiation of therapy, and broadspectrum therapeutic agents with activity against both common and "emerging" pathogens. Until recently, the drugs available to treat invasive fungal infections were limited by their spectrum of activity, the development of resistance, and less than optimal tolerability and drug interaction profiles (15) . To address these issues, a new generation of triazoles, including posaconazole (POS), voriconazole (VRC), and ravuconazole (RAV), has been developed. These agents possess potent broad-spectrum activity and favorable pharmacokinetic profiles (3, 12, 15) . Among these extended-spectrum triazoles, POS has proven to be a potent inhibitor of ergosterol synthesis in both yeasts and molds (19) and to be active against a wide range of pathogens (1, 4, 28, 29) , including Aspergillus spp. (16, 29) and the zygomycetes (7, 34) .
This report summarizes in vitro data for 19,000 clinically important strains of yeasts and molds collected from 200 medical centers worldwide over a 10-year time span. Where available, data are also provided on the comparator drugs itraconazole (ITC), fluconazole (FLC), VRC, and amphotericin B (AMB). Overall, POS exhibited potent broad-spectrum antifungal activity; it was frequently more active than the other azoles, and its spectrum of activity was comparable to that of AMB and superior to those of all other marketed antifungals.
(Part of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 30 October to 2 November 2004.)
MATERIALS AND METHODS
Antifungal agents. POS was prepared at Schering-Plough Research Institute, Kenilworth, NJ. ITC and AMB were obtained from Janssen Pharmaceutica N.V., Beerse, Belgium, and Sigma Chemical Co., St. Louis, MO, respectively. VRC and FLC were obtained from Pfizer Inc., New York, NY.
Susceptibility testing. MIC testing was performed as described in the Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS) documents M27-A2 and M38-A and versions thereof (20, 21) . For slower-growing organisms, such as the dermatophytes, Cryptococcus and Histoplasma spp., if insufficient growth was observed at 48 h then the plates were incubated for longer periods (typically 72 h). Test panels were either prepared in the individual laboratories using drug powders or obtained as frozen panels from Trek Diagnostics Systems Inc. (Cleveland, OH).
Data analysis. Susceptibility data were collected from individual investigators and entered into a global database. Not all strains were tested against all of the comparator drugs; however, all strains in this study were tested against POS. All data relating to control/quality control isolates were excluded from the analysis. In a few instances, an investigator may have tested an isolate more than once; consequently, in the tables, "n" refers to the number of MICs not the number of isolates.
RESULTS

All isolates.
Overall, POS exhibited potent in vitro activity against approximately 19,000 fungal microorganisms. MIC 50 and MIC 90 values for POS were as follows: 0.063 g/ml and 1.0 g/ml, respectively, for all fungi (22,850 MICs); 0.125 g/ml and 1.0 g/ml for all molds (4,499 MICs); and 0.063 g/ml and 1.0 g/ml for all yeasts (18, 351 MICs) .
For the subsets of these 19,000 isolates that were also tested against other antifungal agents, POS was more active than, or within 1 dilution of, ITC, FLC, VRC, and AMB (Table 1) . Although VRC exhibited a lower mean MIC 50 than did POS against yeasts, POS was more active than VRC against molds.
Mold isolates. For subsets of mold isolates tested against each antifungal agent, POS was either more potent than or equivalent to ITC, AMB, and VRC ( 50 and MIC 90 values were 0.125 g/ml and 0.5 g/ml, respectively, whereas for all zygomycetes tested, the MIC 50 and MIC 90 values were 0.5 g/ml and 4.0 g/ml, respectively. In comparisons with other antifungal agents against Aspergillus spp. (1,423 MICs), POS was either more potent than or equivalent to ITC, VRC, and AMB (Table 2 ). However, POS was the only triazole that provided consistent activity against the zygomycetes (86 MICs) ( Table 2) .
Against dimorphic fungi (including Penicillium, Histoplasma, Blastomyces, and Coccidioides spp.), POS was generally more potent than, or equivalent to, ITC and AMB ( Table 2 ). All drugs had limited activity against Fusarium spp. ( Table 2 ). The Fusarium strains most susceptible to POS were F. moniliforme and F. oxysporum.
POS also showed good activity against agents that cause chromoblastomycosis, mycetoma, and phaeohyphomycosis, including Scedosporium apiospermum (though not Scedosporium prolificans) and Exophiala, Alternaria, and Bipolaris spp. (Table  2) , and POS was generally more active than ITC and AMB against these organisms. Against dermatophytes, including Trichophyton rubrum, T. mentagrophytes, and T. tonsurans, POS was more potent than FLC and comparable to ITC (Table 3) .
Yeast isolates. POS showed good activity against Candida spp. (Table 4 ), including those species that are inherently less susceptible to FLC (e.g., Candida spp. C. glabrata, C. krusei, C. guilliermondii, and C. dubliniensis). The strains most susceptible to POS were C. albicans and C. dubliniensis, whereas C. glabrata was the least susceptible. Although POS was slightly less active than VRC against Candida spp., it was more active than either ITC or AMB. Against Cryptococcus spp., POS was more active than FLC and comparable to ITC, VRC, and AMB (Table 4) .
Azole-resistant Candida isolates. Candida isolates with MICs of Ͼ32 g/ml, Ͼ0.5 g/ml, and Ͼ2 g/ml for FLC, ITC, and VRC, respectively, are considered resistant (21) . Of the 6,595 isolates tested against all four azoles, 6.4%, 16.5%, and 3.3% were resistant to FLC, ITC, and VRC, respectively ( Table 5 ). The frequency of isolates with MICs for POS that were Ͼ2 g/ml was 3%. Resistance to one azole significantly impacted susceptibility to the other azoles.
DISCUSSION
The present study has extended the findings of earlier in vitro investigations of the antifungal activity of POS in demonstrating its wide spectrum of activity against more than 19,000 strains of yeasts and molds encountered in infectious disease practice at more than 200 medical centers throughout the world. As well as having good activity against most Candida spp. (including C. glabrata and C. krusei), POS exhibited good activity against the majority of organisms responsible for causing aspergillosis, cryptococcosis, zygomycosis, chromoblastomycosis, mycetoma, and phaeohyphomycosis. In comparison with the other antifungal agents tested (FLC, ITC, VRC, and AMB), POS was generally more potent than FLC and either equipotent to or more potent than ITC, VRC, and AMB. Although POS exhibited slightly higher mean MIC 50 values compared with VRC against Candida spp., including the inherently less susceptible strains C. glabrata and C. krusei, and against Cryptococcus spp., it was generally more active than VRC against molds. Against the zygomycetes, POS was the only triazole that exhibited consistent activity, but it was generally less active against these organisms than AMB. All drugs had limited activity against Fusarium spp. However, successful outcomes have been reported in patients with fusariosis who were treated with (11, 31) . Previous studies comparing the in vitro activity of POS with that of other antifungal agents have described similar findings. In comparison with other triazole agents, POS has generally been reported to have greater activity than FLC and ITC against yeasts such as Candida spp., Cryptococcus spp., and Saccharomyces cerevisiae (1, 4, 13, 23, 27, 28, 30) , although in some studies, it was no more active than ITC against Candida spp. (26) or Cryptococcus neoformans (25) . POS has also proved more active than AMB and flucytosine against most Candida spp. (26) and has been found to have similar activity to VRC against the majority of Candida spp. (23, 30) . However, against C. glabrata, which has proved the least-susceptible Candida species to POS (28, 30) , it was slightly less active than VRC, both in the present study and in an earlier investigation by Pfaller et al. (30) .
Consistent with previous reports (22, 28) , isolates with elevated MICs to one azole were generally less susceptible to all azoles. C. albicans and C. glabrata, in approximately equal numbers, were the species most frequently characterized as being resistant to FLC and VRC. In contrast, the majority of ITC-resistant isolates were C. glabrata. Comparing POS and VRC, the numbers of C. glabrata MICs that were Ͼ2 g/ml (the VRC-resistant breakpoint) were nearly identical for both drugs. However, for both C. albicans and other species of Candida, the number of POS MICs that were Ͼ2 g/ml was nearly twofold lower than for VRC.
In studies focusing on Aspergillus spp., POS has proved more active than both ITC (4, 22) and AMB (22) . In a comparison of POS with RAV, VRC, ITC, and AMB against 239 isolates of Aspergillus spp. and other filamentous fungi (including Fusarium, Rhizopus, and Mucor spp.), POS was the most active agent (94% of isolates inhibited at a MIC of Յ1 g/ml) (29) . In the case of zygomycetes, POS exhibited good activity against 36 zygomycetes belonging to six genera; AMB also showed good activity, VRC was significantly less active, and ITC and terbinafine showed variable activity (7) . Two additional studies compared the activity of POS with those of AMB, VRC, FLC, and ITC or with VRC and caspofungin (CSP) against collections of 37 and 59 zygomycetes, respectively (8, 34) . In both studies, POS was significantly more active than VRC; in the individual All Candida spp. studies, POS was far more active than either FLC (34) or CSP (8) and slightly more active than ITC (34) . In the clinic, POS has been used as salvage therapy to treat over 100 patients with zygomycosis; the rate of success (i.e., either complete or partial response) was at least 60% (10, 35) .
In agreement with our findings, good activity against Coccidioides immitis has been reported in other studies, although POS proved slightly less active than ITC in one study (9) . Both this and previous studies demonstrated that POS is less active against Scedosporium prolificans than against S. apiospermum (5). Similarly, although POS was not compared with VRC against these organisms in the data presented above, other investigators have shown that POS is significantly less active than VRC against S. prolificans and slightly less active than VRC against S. apiospermum (5, 18).
The molecular basis for the enhanced in vitro activity of POS over the other azoles remains to be determined. At a first approximation, the in vitro activity of a drug is governed by its ability to accumulate within the cell coupled with its affinity for its target site. Several lines of evidence suggest that decreased susceptibility to azoles results from both changes in intracellular accumulation and changes in the target site (6, 14, 33) . The azole target site is 14␣-demethylase (CYP51), which is located predominantly in the endoplasmic reticulum. None of the fungal CYP51 enzymes have been crystallized; therefore, information on the way in which the azoles bind to the protein has come primarily from homology modeling studies. One recent study suggested that the long side chain of POS and ITC, a side chain that is absent in VRC and FLC, helps stabilize binding of these azoles to CYP51; this appears to be particularly true for CYP51 proteins with mutations close to the active site (36) . This model also suggested that mutations that interfered with binding of the long side chain negatively impacted POS and ITC more than they impacted FLC and VRC. It is conceivable that an increased affinity for CYP51 is responsible for the unique activity of POS against the zygomycetes. In this regard, expression of the CYP51 from Rhizopus oryzae in an azolesusceptible Saccharomyces cerevisiae strain resulted in a 4-fold decrease in susceptibility to POS and a Ͼ250-fold decrease in susceptibility to VRC; there were no changes in susceptibility to either AMB or CSP (unpublished data). These data suggest that for R. oryzae, and possibly for other zygomycetes, the nature of the interaction between drug and target protein is a major determinant of susceptibility. With regard to drug accumulation, the level of efflux pump expression can strongly influence the susceptibility of a cell to azoles (33) . Studies, primarily using yeasts, demonstrated that whereas all azoles appear to be substrates for the ATP-dependent pumps, POS and ITC are not substrates for the major facilitator encoded by MDR1 (D. Sanglard, F. Ischer, and J. Bille, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-221, p. 379, 2002); again, the molecular basis for these differences remains to be established.
In summary, the differences between POS and the other triazoles described above may account for the unusually broad spectrum of activity of POS and may also be important in combating the increase in triazole resistance currently being observed among some fungal pathogens, notably Candida spp., for which multiple molecular mechanisms may be responsible for the decrease in susceptibility. 
